Clinical Focus ›› 2021, Vol. 36 ›› Issue (9): 856-860.doi: 10.3969/j.issn.1004-583X.2021.09.018
Previous Articles Next Articles
Received:
2021-08-02
Online:
2021-09-20
Published:
2021-10-05
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.09.018
[1] |
Floreani A, Restrepo-Jimenez P, Secchi MF, et al. Etiopathogenesis of autoimmune hepatitis[J]. J Autoimmun, 2018, 95(12):133-143.
doi: 10.1016/j.jaut.2018.10.020 URL |
[2] |
Czaja AJ. Global disparities and their implications in the occurrence and outcome of autoimmune hepatitis[J]. Dig Dis Sci, 2017, 62(9):2277-2292.
doi: 10.1007/s10620-017-4675-y URL |
[3] |
Yamamoto E, Jorgensen TN. Immunological effects of vitamin D and their relations to autoimmunity[J]. J Autoimmun, 2019, 100:7-16.
doi: S0896-8411(19)30033-2 pmid: 30853311 |
[4] |
Udomsinprasert W, Jittikoon J. Vitamin D and liver fibrosis: Molecular mechanisms and clinical studies[J]. Biomed Pharmacother, 2019, 109:1351-1360.
doi: S0753-3322(18)36703-9 pmid: 30551386 |
[5] |
Jiang X, O'Reilly PF, Aschard H, et al. Genome-wide association study in 79, 366 European-ancestry individuals informs the genetic architecture of 25-hydroxyvitamin D levels[J]. Nat Commun, 2018, 9(1):260.
doi: 10.1038/s41467-017-02662-2 pmid: 29343764 |
[6] |
Chen EQ, Shi Y, Tang H. New insight of vitamin D in chronic liver diseases[J]. Hepatobiliary Pancreat Dis Int, 2014, 13(6):580-585.
doi: 10.1016/S1499-3872(14)60295-2 URL |
[7] |
Adorini L. Vitamin D receptor polymorphisms in primary biliary cirrhosis: A functional connection?[J]. J Hepatol, 2009, 50(6):1071-1073.
doi: 10.1016/j.jhep.2009.03.005 URL |
[8] |
Adams JS, Hewison M. Unexpected actions of vitamin D: New perspectives on the regulation of innate and adaptive immunity[J]. Nat Clin Pract Endocrinol Metab, 2008, 4(2):80-90.
doi: 10.1038/ncpendmet0716 pmid: 18212810 |
[9] |
Penna G, Adorini L. 1 Alpha, 25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation[J]. J Immunol, 2000, 164(5):2405-2411.
pmid: 10679076 |
[10] |
Sassi F, Tamone C, d'Amelio P. Vitamin D: Nutrient, hormone, and immunomodulator[J]. Nutrients, 2018, 10(11):1656.
doi: 10.3390/nu10111656 URL |
[11] |
Xie Z, Chen J, Zheng C, et al. 1, 25-dihydroxyvitamin D3-induced dendritic cells suppress experimental autoimmune encephalomyelitis by increasing proportions of the regulatory lymphocytes and reducing T helper type 1 and type 17 cells[J]. Immunology, 2017, 152(3):414-424.
doi: 10.1111/imm.2017.152.issue-3 URL |
[12] | Luong KV, Nguyen LT. The role of vitamin d in autoimmune hepatitis[J]. J Clin Med Res, 2013, 5(6):407-415. |
[13] |
Arai T, Atsukawa M, Tsubota A, et al. Association of vitamin D levels and vitamin D-related gene polymorphisms with liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease[J]. Dig Liver Dis, 2019, 51(7):1036-1042.
doi: 10.1016/j.dld.2018.12.022 URL |
[14] |
Reiter FP, Hohenester S, Nagel JM, et al. 1, 25-(OH)(2)-vitamin D(3) prevents activation of hepatic stellate cells in vitro and ameliorates inflammatory liver damage but not fibrosis in the Abcb4(-/-) model[J]. Biochem Biophys Res Commun, 2015, 459(2):227-233.
doi: 10.1016/j.bbrc.2015.02.074 URL |
[15] |
Ding N, Yu RT, Subramaniam N, et al. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response[J]. Cell, 2013, 153(3):601-613.
doi: 10.1016/j.cell.2013.03.028 URL |
[16] |
Wahsh E, Abu-Elsaad N, El-Karef A, et al. The vitamin D receptor agonist, calcipotriol, modulates fibrogenic pathways mitigating liver fibrosis in-vivo: An experimental study[J]. Eur J Pharmacol, 2016, 789:362-369.
doi: S0014-2999(16)30493-9 pmid: 27477355 |
[17] |
Hu XD, Jiang SL, Liu CH, et al. Preventive effects of 1, 25-(OH)2VD3 against ConA-induced mouse hepatitis through promoting vitamin D receptor gene expression[J]. Acta Pharmacol Sin, 2010, 31(6):703-708.
doi: 10.1038/aps.2010.53 URL |
[18] |
Ebadi M, Bhanji RA, Mazurak VC, et al. Severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis[J]. Aliment Pharmacol Ther, 2019, 49(2):173-182.
doi: 10.1111/apt.15029 URL |
[19] |
Zhang Y, Leung DY, Goleva E. Vitamin D enhances glucocorticoid action in human monocytes: Involvement of granulocyte-macrophage colony-stimulating factor and mediator complex subunit 14[J]. J Biol Chem, 2013, 288(20):14544-14553.
doi: 10.1074/jbc.M112.427054 pmid: 23572530 |
[20] |
Zhang Y, Leung DY, Richers BN, et al. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1[J]. J Immunol, 2012, 188(5):2127-2135.
doi: 10.4049/jimmunol.1102412 pmid: 22301548 |
[21] |
Bellan M, Andreoli L, Mele C, et al. Pathophysiological role and therapeutic implications of vitamin D in autoimmunity: Focus on chronic autoimmune diseases[J]. Nutrients, 2020, 12(3):789.
doi: 10.3390/nu12030789 URL |
[22] |
Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline[J]. J Clin Endocrinol Metab, 2011, 96(7):1911-1930.
doi: 10.1210/jc.2011-0385 URL |
[23] |
Duarte C, Carvalheiro H, Rodrigues AM, et al. Prevalence of vitamin D deficiency and its predictors in the Portuguese population: A nationwide population-based study[J]. Arch Osteoporos, 2020, 15(1):36.
doi: 10.1007/s11657-020-0695-x pmid: 32124071 |
[24] |
Lee WS, Jalaludin MY, Wong SY, et al. Vitamin D non-sufficiency is prevalent in children with chronic liver disease in a tropical country[J]. Pediatr Neonatol, 2019, 60(1):12-18.
doi: 10.1016/j.pedneo.2018.03.011 URL |
[25] |
Eliades M, Spyrou E, Agrawal N, et al. Meta-analysis: vitamin D and non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2013, 38(3):246-254.
doi: 10.1111/apt.2013.38.issue-3 URL |
[26] |
Kitson MT, Roberts SK. D-livering the message: the importance of vitamin D status in chronic liver disease[J]. J Hepatol, 2012, 57(4):897-909.
doi: 10.1016/j.jhep.2012.04.033 URL |
[27] |
Nashold FE, Spach KM, Spanier JA, et al. Estrogen controls vitamin D3-mediated resistance to experimental autoimmune encephalomyelitis by controlling vitamin D3 metabolism and receptor expression[J]. J Immunol, 2009, 183(6):3672-3681.
doi: 10.4049/jimmunol.0901351 pmid: 19710457 |
[28] |
Czaja AJ, Montano-Loza AJ. Evolving role of vitamin D in immune-mediated disease and its implications in autoimmune hepatitis[J]. Dig Dis Sci, 2019, 64(2):324-344.
doi: 10.1007/s10620-018-5351-6 URL |
[29] |
Vogel A, Strassburg CP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis[J]. Hepatology, 2002, 35(1):126-131
doi: 10.1053/jhep.2002.30084 URL |
[30] |
Fan L, Tu X, Zhu Y, et al. Genetic association of vitamin D receptor polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese[J]. J Gastroenterol Hepatol, 2005, 20(2):249-255.
doi: 10.1111/jgh.2005.20.issue-2 URL |
[31] |
Jeong MS, Kim JY, Lee HI, et al. Calcitriol may down-regulate mRNA over-expression of Toll-like receptor-2 and -4, LL-37 and proinflammatory cytokines in cultured human keratinocytes[J]. Ann Dermatol, 2014, 26(3):296-302.
doi: 10.5021/ad.2014.26.3.296 pmid: 24966627 |
[32] |
Roth CL, Elfers CT, Figlewicz DP, et al. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation[J]. Hepatology, 2012, 55(4):1103-1111.
doi: 10.1002/hep.24737 URL |
[33] | Tao S, Zhang H, Zhao Q, et al. Correlation of vitamin D with inflammatory factors, oxidative stress and T cell subsets in patients with autoimmune hepatitis[J]. Exp Ther Med, 2020, 19(5):3419-3424. |
[34] |
Paternostro R, Wagner D, Reiberger T, et al. Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis[J]. Wien Klin Wochenschr, 2017, 129(1-2):8-15.
doi: 10.1007/s00508-016-1127-1 pmid: 27888359 |
[35] |
Efe C, Kav T, Aydin C, et al. Low serum vitamin D levels are associated with severe histological features and poor response to therapy in patients with autoimmune hepatitis[J]. Dig Dis Sci, 2014, 59(12):3035-3042.
doi: 10.1007/s10620-014-3267-3 URL |
[36] |
Bouillon R. Comparative analysis of nutritional guidelines for vitamin D[J]. Nat Rev Endocrinol, 2017, 13(8):466-479.
doi: 10.1038/nrendo.2017.31 pmid: 28387318 |
[1] | . [J]. Clinical Focus, 2024, 39(2): 177-182. |
[2] | . [J]. Clinical Focus, 2024, 39(1): 84-87. |
[3] | Yang Zhibin, Shao Yanfang, Pan Li, Yang Yanxia, Yang Yuxi, Zhao Lihui, Zeng Rongkun, Li Yang, Wang Qiaofeng, Wang Cong, Ma Shiwu. Efficacy of magnesium isoglycyrrhizinate in anti-tuberculosis drug-induced liver injury [J]. Clinical Focus, 2021, 36(11): 972-975. |
[4] | . [J]. Clinical Focus, 2021, 36(6): 574-576. |
[5] | . [J]. CLINICAL FOCUS, 2014, 29(2): 202-203. |
[6] | . [J]. CLINICAL FOCUS, 2013, 28(7): 812-813. |
[7] | WANG Pu;LIU Jiang-wen;TONG De-feng;CUI Yong. Effects of 15-deoxy-prostaglandin J2 on expression of proliferator-activated receptor γ,tumor necrosis factor-α and interleukin-6 in liver tissue of rats with nonalcoholic fatty liver disease [J]. Clinical Focus, 2013, 28(4): 412-0. |
[8] | . [J]. Clinical Focus, 2012, 27(22): 1993-1994. |
[9] | . [J]. Clinical Focus, 2012, 27(18): 1610-1611. |
[10] | ZHANG Jun-xia;LIU Jun-juan;LI Jia. Clinical characteristics of 42 autoimmune hepatitis patients [J]. Clinical Focus, 2012, 27(12): 1050-1053. |
[11] | . [J]. Clinical Focus, 2011, 26(24): 2170-2171. |
[12] | . [J]. CLINICAL FOCUS, 2011, 26(20): 1811-1813. |
[13] | ZHAO Zhao-xia;YE Li-hong;LU Jian-hua;YANG Li;LIU Yan-chao;LIU Yu-zhen;HOU Jun-liang;DAI Er-hei . Quantification of liver hepatitis B virus covalently closed circular DNA in patients with chronic hepatitia B [J]. CLINICAL FOCUS, 2011, 26(13): 1108-1110. |
[14] | . [J]. CLINICAL FOCUS, 2010, 25(24): 2174-2174. |
[15] | . [J]. CLINICAL FOCUS, 2010, 25(23): 2106-2108. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||